bility of the combined action of RA and FGF4 to direct differentiation of PDX1-expressing cells, we repeated our protocol three times using cell line 19276073 Hues3 at different passages. More specifically, passage 68, 75 and 76 were used. In order to get some relevant estimation of the AZD-5438 site magnitude of PDX1-expression in differentiated hESC at day 16, the expression was compared to PDX1-expression in human islets. PDX1-mRNA levels in differentiated hESC were approximately 50% of the levels detected in human islets. In order to analyze the real-time PCR data, the lowest value of each data set was set to one and all other values were related to this. Following this procedure, a mean value was calculated for each of the duplicate or triplicate samples. In some cases, the non-treated cells did not have any measurable level of PDX1-transcripts and consequently Ct-values were set to 45. Moreover, to further establish the robustness of this protocol, its cell line specificity was tested. For this purpose, the RA/FGF4 protocol was tested on another hESC line: Hues-15. Indeed, RA/FGF4 effectively induced PDX1 expression in Hues-15. Thus, the fact that RA and FGF4 significantly increased PDX1 mRNA expression in Hues-15 and Hues-3 subclone 52, suggests that the ability of these factors to direct differentiation of AA-induced hESC into PDX1+ cells is cell line independent. When the D’Amour protocol was tested on cell line Hues-1, cells died at stage three. 
However, with cell line Hues-3, a small number of PDX1+ cells was obtained at stage three. Still, cells did not survive further treatment onto stage four and five. Importantly, these PDX1 expression levels were never as high as with our RA/FGF4-protocol. PDX1+ Foregut from hESCs 6 PDX1+ Foregut from hESCs 7 PDX1+ Foregut from hESCs FGF4 and RA direct differentiation of hESCs into PDX1+ foregut endoderm In order to determine whether the induced 9128839 PDX1+ cells represents posterior foregut pancreatic endoderm or non-pancreatic foregut endoderm, the expression of markers characteristic for such cell types were examined. Whereas the general gut endoderm marker FOXA2 was expressed at high levels at all time points and unaffected by RA/FGF4-treatment, the effect on expression of the midgut/ posterior gut endoderm marker CDX2 varied. Consistent with the increase in PDX1 mRNA expression, a corresponding increase in the transcription of the foregut endoderm markers HNF6 and SOX9 was observed. However, mRNA expression of markers characteristic of posterior foregut pancreatic endoderm, such as PTF1a and NKX6.1 was very low, suggesting that the combined action of RA and FGF4 results in induction of PDX1+ foregut endoderm. In addition, mRNA expression of NKX2.2, NKX2.1, Glucagon and Insulin was also very low or undetectable. Thus, we speculate that the cells obtained with our protocol represent multipotent foregut endoderm with the potential to become pancreatic, posterior stomach, or duodenal endoderm. Control cells, i.e. cells that subsequent to the AA-induction were not treated with FGF4 and RA, adopted a hepatic fate as determined by an upregulation of liver progenitor/hepatocyte marker expression, including albumin, a-fetoprotein and prospero-related homeobox-1 . To more directly examine the nature of the PDX1+ cells, immunofluorescence stainings with antibodies against gut endoderm, foregut endoderm, and posterior pancreatic foregut endoderm were performed. All PDX1+ cells, which primarily were found in clusters, expre
